Trials / Completed
CompletedNCT01193127
Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 223 (actual)
- Sponsor
- Omeros Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether the use of OMS302 (the study drug) in individuals undergoing Cataract Extraction with Lens Replacement (CELR) surgery is safe and effective at maintaining an adequately dilated pupil during surgery and reducing post-operative symptoms of discomfort (such as eye pain and irritation).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OMS302 Solution | |
| DRUG | OMS302 Mydriatic Solution | |
| DRUG | OMS302 Anti-inflammatory Solution | |
| DRUG | Balanced Salt Solution (BSS) Solution |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2011-01-01
- Completion
- 2011-02-01
- First posted
- 2010-09-01
- Last updated
- 2014-08-28
- Results posted
- 2014-08-28
Locations
24 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01193127. Inclusion in this directory is not an endorsement.